Natixis Advisors LLC Increases Position in Exelixis, Inc. (NASDAQ:EXEL)

Natixis Advisors LLC increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 26.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 29,113 shares of the biotechnology company’s stock after acquiring an additional 6,051 shares during the period. Natixis Advisors LLC’s holdings in Exelixis were worth $755,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EXEL. Hsbc Holdings PLC grew its holdings in shares of Exelixis by 45.3% in the second quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock worth $2,031,000 after purchasing an additional 28,126 shares during the last quarter. Farallon Capital Management LLC boosted its position in Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after buying an additional 424,000 shares during the period. Los Angeles Capital Management LLC grew its stake in Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 991,494 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 20,641 shares during the period. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Exelixis in the third quarter valued at approximately $577,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Exelixis stock opened at $35.93 on Thursday. Exelixis, Inc. has a one year low of $19.20 and a one year high of $36.73. The stock has a market cap of $10.26 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 0.92 and a beta of 0.51. The stock has a 50-day moving average of $30.25 and a two-hundred day moving average of $25.83.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Exelixis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share. As a group, sell-side analysts predict that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on EXEL. Guggenheim boosted their price target on Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Truist Financial increased their price target on Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. TD Cowen increased their price target on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada reissued an “outperform” rating and set a $34.00 price target on shares of Exelixis in a research report on Wednesday, October 30th. Finally, Stifel Nicolaus increased their price target on Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average target price of $31.44.

Insider Activity at Exelixis

In other Exelixis news, Director George Poste sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $34.00, for a total value of $1,020,000.00. Following the sale, the director now directly owns 169,020 shares of the company’s stock, valued at approximately $5,746,680. This trade represents a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the sale, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. The trade was a 3.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 279,736 shares of company stock worth $9,308,410. 2.85% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.